Salisbury, UK, 7th September 2011: NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, will host a new interactive webinar on the latest developments in the methods of exosome characterization using the unique Nanoparticle Tracking Analysis technology, NTA. It will be held on Thursday 22nd September, 0700 PST, 1000 EST, 1500 BST, then again live, two hours later at 0900 PST, 1200 EST, 1700 BST.
The past few months have seen a growing number of papers from researchers reporting their work in to the characterization of exosomes. Notable in these was the landmark paper published in NanoMedicine by Sargent et al from the Nuffield Department of Obstetrics & Gynaecology, Oxford University, UK, entitled “Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis.”
This latest webinar is aimed at those with a similar interest in the detection and speciation of exosomes and micro-vesicles. It will be moderated and fully interactive. Questions will be encouraged during and at the end of the presentations.
Until recent publications, exosomes research has been constrained by a lack of suitable methods of characterization. Nanoparticle Tracking Analysis (NTA) addresses this need, allowing exosomes and microvesicles in the range of 30 – 1000 nm in liquid suspension to be directly and individually visualized in real-time. Thus, NTA provides high-resolution particle size distribution profiles and concentration measurements. The technique is fast, robust, accurate and cost effective, representing an attractive alternative or complement to existing methods. Specific exosomes can be imaged and characterized through suitable labeling with a fluorescent marker with a range of excitation wavelengths available.
Join colleagues across the world for this interactive webinar led by NanoSight’s founder and CTO, Dr Bob Carr. The anticipated duration of the webinar is 40 minutes including any questions. To attend this webinar, please use this registration link: http://www.nanosight.com/webinar.
NanoSight would also like to take this opportunity to inform the exosomes community of their participation in the 2011 Exosomes and Microvesicles Conference & Exhibition in Orlando, Florida October 15-17. As well as exhibiting, NanoSight will be running delegates’ samples. Delegates should contact NanoSight before the meeting about the samples they propose to bring along: firstname.lastname@example.org.
To learn more about nanoparticle characterization using NTA, please visit the company website (www.nanosight.com) and register for the latest issue of NanoTrail, the company’s electronic newsletter.
Dr Bob Carr, Founder and CTO of NanoSight, will lead the Exosomes characterization webinar
To download a high resolution version (1373 x 897 pixels), please click on the image above.
NanoSight delivers the world’s most versatile and proven multi-parameter nanoparticle analysis in a single instrument.
NanoSight visualizes, measures and characterizes virtually all nanoparticles. Particle size, concentration, Zeta potential and aggregation can all be analyzed while a fluorescence mode provides speciation (differentiation) of labeled particles. NanoSight presents real time monitoring of the subtle changes in the characteristics of particle populations with all of these analyses uniquely confirmed by visual validation.
NanoSight’s “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm, dependent on material, and measures the size of each particle from direct observations of diffusion. This particle-by-particle methodology goes beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions. Additionally, NanoSight measures concentration and validates data with information-rich video files of the particles moving under Brownian motion.
NanoSight’s comprehensive characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, in nanotoxicology and in biodiagnostics. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner.
NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles. As functionalized nanoparticles increasingly fulfill their potential in biodiagnostics, NanoSight is ever more the analytical platform of choice.
NanoSight demonstrates worldwide success through rapid adoption of NTA, having installed more than 350 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. In addition to this user base more than 250 third party papers citing NanoSight results consolidate NanoSight’s leadership position in nanoparticle characterization.
For more information, visit the NanoSight website (www.nanosight.com).
For further information
Please contact NanoSight direct or their marketing agency, NetDyaLog Limited:
Amesbury SP4 7RT
T +44 (0) 1980 676060
F +44 (0) 1980 624703
39 de Bohun Court
Essex CB10 2BA
T +44 (0) 1799 521881
M +44 (0) 7843 012997